Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou 646000, Sichuan Province, China.
Department of Clinical laboratory, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China.
Exp Mol Pathol. 2021 Jun;120:104643. doi: 10.1016/j.yexmp.2021.104643. Epub 2021 Apr 28.
This research aims to investigate the relationship between the expression of microRNA-199b-5p (miR-199b-5p) and soluble human leukocyte antigen G (sHLA-G) in thyroid cancer tissues and its clinicopathological characteristics, as well as its impact on prognosis.
Frozen tissues and serum from 85 patients with thyroid cancer, 27 with thyroid adenoma, 19 with Hashimoto's thyroiditis and 14 with nodular goiter from February 2014 to March 2016 were sampled. The miR-199b-5pmRNA expression in tissues was analyzed by real-time quantitative PCR. Serum HLA-G expression was detected by ELISA, and the relationship between s HLA-G expression and clinicopathological characteristics of thyroid cancer was analyzed. The relationship between 1- and 3-year survival rates of all patients and the expression of both detection indexes was observed.
Compared with normal thyroid specimens, nodular goiter, Hashimoto's thyroiditis, thyroid adenoma and thyroid cancer patients, the relative expression of miR-199b-5pmRNA in thyroid cancer tissues was the lowest, while that of s HLA-G was the highest in serum of patients (P < 0.05). The levels of miR-199b-5pmRNA and serum s HLA-G in tumor tissues were correlated with clinical pathological features such as tumor size, differentiation degree, capsule invasion, lymph node metastasis, etc. (all P < 0.05). The expression of miR-199b-5pmRNA and s HLA-G were negatively correlated. ROC curve identified that miR-199b-5pmRNA and HLA-g had obvious diagnostic value for thyroid cancer patients. Kaplan-Meier survival analysis manifested that the 1- and 3-year survival rates of the miR-199b-5p low expression group in thyroid cancer tissues were lower than the miR-199b-5p high expression group, and the rates of the s HLA-G low expression group were higher than the s HLA-G high expression group.
The miR-199b-5p expression in thyroid cancer tissues and HLA-g in serum were related to tumor size, differentiation degree, capsular invasion, lymph node metastasis and other characteristics. MiR-199b-5p may jointly affect the progression of thyroid cancer with s HLA-G.
本研究旨在探讨微小 RNA-199b-5p（miR-199b-5p）在甲状腺癌组织中的表达与可溶性人类白细胞抗原 G（sHLA-G）及其与临床病理特征的关系，以及对预后的影响。
收集 2014 年 2 月至 2016 年 3 月期间 85 例甲状腺癌患者、27 例甲状腺腺瘤患者、19 例桥本甲状腺炎患者和 14 例结节性甲状腺肿患者的冷冻组织和血清。采用实时定量 PCR 分析组织中 miR-199b-5p mRNA 的表达，采用 ELISA 法检测血清 HLA-G 表达，分析 sHLA-G 表达与甲状腺癌临床病理特征的关系。观察所有患者 1 年和 3 年生存率与两种检测指标表达的关系。
与正常甲状腺标本相比，甲状腺癌患者结节性甲状腺肿、桥本甲状腺炎、甲状腺腺瘤和甲状腺癌患者的 miR-199b-5p mRNA 相对表达量最低，而血清 s HLA-G 水平最高（P<0.05）。肿瘤组织中 miR-199b-5p mRNA 和血清 s HLA-G 水平与肿瘤大小、分化程度、包膜浸润、淋巴结转移等临床病理特征相关（均 P<0.05）。miR-199b-5p mRNA 和 s HLA-G 表达呈负相关。ROC 曲线表明，miR-199b-5p mRNA 和 HLA-g 对甲状腺癌患者具有明显的诊断价值。Kaplan-Meier 生存分析表明，甲状腺癌组织中 miR-199b-5p 低表达组 1 年和 3 年生存率低于 miR-199b-5p 高表达组，s HLA-G 低表达组生存率高于 s HLA-G 高表达组。
甲状腺癌组织中 miR-199b-5p 的表达和血清中 HLA-g 与肿瘤大小、分化程度、包膜浸润、淋巴结转移等特征有关。miR-199b-5p 可能与 s HLA-G 共同影响甲状腺癌的进展。
